Journal of Comprehensive Pediatrics

Published by: Kowsar

Preliminary Investigation on Duloxetine Efficacy in the Treatment of Children With Attention-Deficit Hyperactivity Disorder

Nasrin Dodangi 1 , Nastaran Habibi 1 , * and Ali Nazeri astaneh 1
Authors Information
1 Department of Psychiatry, University of Social Welfare and Rehabilitation Sciences, Tehran, IR Iran
Article information
  • Journal of Comprehensive Pediatrics: November 01, 2015, 6 (4); e27482
  • Published Online: November 23, 2015
  • Article Type: Research Article
  • Received: April 27, 2015
  • Revised: October 25, 2015
  • Accepted: November 14, 2015
  • DOI: 10.17795/compreped-27482

To Cite: Dodangi N, Habibi N, Nazeri astaneh A. Preliminary Investigation on Duloxetine Efficacy in the Treatment of Children With Attention-Deficit Hyperactivity Disorder, J Compr Ped. 2015 ; 6(4):e27482. doi: 10.17795/compreped-27482.

Abstract
Copyright © 2015, Iranian Society of Pediatrics. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 2013; : 466-71
  • 2. Murray DW, Arnold LE, Swanson J, Wells K, Burns K, Jensen P, et al. A clinical review of outcomes of the multimodal treatment study of children with attention-deficit/hyperactivity disorder (MTA). Curr Psychiatry Rep. 2008; 10(5): 424-31[PubMed]
  • 3. Sadock BJ, Sadock VA. Kaplan and Sadock's comprehensive textbook of psychiatry . 2005;
  • 4. Leonard BE, McCartan D, White J, King DJ. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol. 2004; 19(3): 151-80[DOI][PubMed]
  • 5. Ratner S, Laor N, Bronstein Y, Weizman A, Toren P. Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2005; 44(5): 428-33[DOI][PubMed]
  • 6. Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009; 11(3): 203-26[DOI][PubMed]
  • 7. Findling RL, Greenhill LL, McNamara NK, Demeter CA, Kotler LA, O'Riordan MA, et al. Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2007; 17(4): 433-45[DOI][PubMed]
  • 8. Mukaddes NM, Abali O. Venlafaxine in children and adolescents with attention deficit hyperactivity disorder. Psychiatry Clin Neurosci. 2004; 58(1): 92-5[PubMed]
  • 9. Green WH. Child and Adolescent Clinical Psychopharmacology. 2007; : 716
  • 10. Hudson JI, Wohlreich MM, Kajdasz DK, Mallinckrodt CH, Watkin JG, Martynov OV. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol. 2005; 20(5): 327-41[DOI][PubMed]
  • 11. Carter NJ, McCormack PL. Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009; 23(6): 523-41[DOI][PubMed]
  • 12. Gupta S, Nihalani N, Masand P. Duloxetine: review of its pharmacology, and therapeutic use in depression and other psychiatric disorders. Ann Clin Psychiatry. 2007; 19(2): 125-32[DOI][PubMed]
  • 13. Khan AY, Macaluso M. Duloxetine for the treatment of generalized anxiety disorder: a review. Neuropsychiatr Dis Treat. 2009; 5: 23-31[PubMed]
  • 14. Prakash A, Lobo E, Kratochvil CJ, Tamura RN, Pangallo BA, Bullok KE, et al. An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression. J Child Adolesc Psychopharmacol. 2012; 22(1): 48-55[DOI][PubMed]
  • 15. Meighen KG. Duloxetine treatment of pediatric chronic pain and co-morbid major depressive disorder. J Child Adolesc Psychopharmacol. 2007; 17(1): 121-7[DOI][PubMed]
  • 16. Desarkar P, Das A, Sinha VK. Duloxetine for childhood depression with pain and dissociative symptoms. Eur Child Adolesc Psychiatry. 2006; 15(8): 496-9[DOI][PubMed]
  • 17. Wernicke JF, Gahimer J, Yalcin I, Wulster-Radcliffe M, Viktrup L. Safety and adverse event profile of duloxetine. Expert Opin Drug Saf. 2005; 4(6): 987-93[DOI][PubMed]
  • 18. Wernicke J, Lledo A, Raskin J, Kajdasz DK, Wang F. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf. 2007; 30(5): 437-55[PubMed]
  • 19. Zhang L, Chappell J, Gonzales CR, Small D, Knadler MP, Callaghan JT, et al. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharmacol. 2007; 49(3): 146-53[DOI][PubMed]
  • 20. Gahimer J, Wernicke J, Yalcin I, Ossanna MJ, Wulster-Radcliffe M, Viktrup L. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin. 2007; 23(1): 175-84[DOI][PubMed]
  • 21. Dulkan MK, Mina K. Dulkan's Textbook of Child and Adolescent Psychiatry. 2010;
  • 22. Ghanizadeh A, Mohammadi MR, Yazdanshenas A. Psychometric properties of the Farsi translation of the Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version. BMC Psychiatry. 2006; 6: 10[DOI][PubMed]
  • 23. Shahrivar Z, Kousha M, Moallemi S, Tehrani-Doost M, Alaghband-Rad J. The reliability and validity of kiddie-schedule for affective disorders and schizophrenia- present and lifetime. Child Adolescent Ment Health. 2010; 15(2): 97-102[DOI]
  • 24. Conners CK, Barkley RA. Rating scales and checklists for child psychopharmacology. Psychopharmacol Bull. 1985; 21(4): 809-43[PubMed]
  • 25. Conners CK, Sitarenios G, Parker JD, Epstein JN. The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998; 26(4): 257-68[PubMed]
  • 26. Reynolds CR, Richmond BO. What I Think and Feel: a revised measure of Children's Manifest Anxiety. J Abnorm Child Psychol. 1997; 25(1): 15-20[PubMed]
  • 27. Kovacs M. The Children's Depression, Inventory (CDI). Psychopharmacol Bull. 1985; 21(4): 995-8[PubMed]
  • 28. Rajabi G,H,R. An investigation of reliability and validity of child depression inventory in 13 to 15 years old adolescents. J Psychol Education. 2007; 37: 23-46
  • 29. Taghavi S,M,R. The normalization of revised children manifest anxiety scale (RCMAS) for students in Shiraz. J Social Sciences Hum Shiraz. 2006; 22(4): 179-88
  • 30. Tourjman SV, Bilodeau M. Improvement with duloxetine in an adult ADHD patient. J Atten Disord. 2009; 13(1): 95-6[DOI][PubMed]
  • 31. Niederhofer H. Duloxetine May Improve Some Symptoms of Attention Deficite/Hyperactivity Disorder ,Prim Care Companion . J Clin Psychiatry. 2010; 12(2)
  • 32. Mahmoudi-Gharaei J, Dodangi N, Tehrani-Doost M, Faghihi T. Duloxetine in the treatment of adolescents with attention deficit/hyperactivity disorder: an open-label study. Hum Psychopharmacol. 2011; 26(2): 155-60[DOI][PubMed]
  • 33. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002; 159(11): 1896-901[DOI][PubMed]
  • 34. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001; 108(5)[PubMed]
  • 35. Olvera RL, Pliszka SR, Luh J, Tatum R. An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol. 1996; 6(4): 241-50[PubMed]
  • 36. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002; 63(4): 308-15[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments